Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Evobrutinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck KGaA suffers major blow as MS drug fails in late-stage trials
    Merck KGaA suffers major blow as MS drug fails in late-stage trials

    06 Dec 2023

    // Ludwig Burger REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/merck-kgaa-says-ms-drug-fails-late-stage-trials-2023-12-05/

    Ludwig Burger REUTERS
    06 Dec 2023
    Share Share
    Merck KGaA's MS drug passes durability test ahead of ph. 3 data
    Merck KGaA's MS drug passes durability test ahead of ph. 3 data

    12 Oct 2023

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/merck-kgaa-hold-still-clouding-prospects-guides-ms-drug-past-durability-test-ahead-phase-3

    Nick Paul Taylor FIERCE BIOTECH
    12 Oct 2023
    Share Share
    Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit
    Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit

    11 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231010955535/en

    BUSINESSWIRE
    11 Oct 2023
    Share Share
    Merck KGaA's BTK inhibitor hit by partial clinical hold over safety concern
    Merck KGaA's BTK inhibitor hit by partial clinical hold over safety concern

    13 Apr 2023

    // Amber Tong ENDPTS

    https://endpts.com/merck-kgaas-btk-inhibitor-hit-by-partial-clinical-hold-over-safety-concern-but-phiii-readout-unaffected/

    Amber Tong ENDPTS
    13 Apr 2023
    Share Share
    Initiation of New Patients on Evobrutinib Paused in the U.S.
    Initiation of New Patients on Evobrutinib Paused in the U.S.

    12 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230412005160/en

    BUSINESSWIRE
    12 Apr 2023
    Share Share
    Merck Highlights New Four-Year Efficacy and Safety Data for Evobrutinib
    Merck Highlights New Four-Year Efficacy and Safety Data for Evobrutinib

    23 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230223005130/en

    BUSINESSWIRE
    23 Feb 2023
    Share Share